Acadia Pharmaceuticals Q3 net income falls 25% to $53.52 million
Bitget2026/11/04 21:27- Acadia Pharmaceuticals’ third-quarter 2026 net income fell 25% year-over-year to $53.52 million.
- Total revenues rose 23% year-over-year to $342.29 million.
- Research and development expenses dropped 13% to $76.28 million, with 2026 guidance lowered to $325 million–$340 million.
- DAYBU launched in Germany in early October following European Commission approval for treating Rett syndrome.
- Two Phase 2 readouts are expected in 2027: ACP-211 in major depressive disorder and remlifanserin in Lewy body dementia psychosis.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Unity and Nvidia’s investment division join Emulate's $700 million funding round
Anthropic IPO frenzy! Subscription demand several times oversubscribed, targeting a valuation of 1.4 trillions USD
Anthropic's upcoming IPO has sparked strong market enthusiasm, with subscription demand reaching several times the offering. The company plans to raise up to 90.4 billions USD through the IPO and private placement, potentially setting a new record for the largest listing in history. Although its valuation target of 1.4 trillions USD is slightly lower than previously expected, the market response remains extremely enthusiastic, fueled by robust institutional anchor demand.
Crypto prices
More
